Table of Contents
1 Industry Outlook 9
1.1 Industry Overview 9
1.2 Industry Trends 9
2 Report Outline 10
2.1 Report Scope 10
2.2 Report Summary 10
2.3 Research Methodology 11
2.4 Report Assumptions 12
3 Market Snapshot 12
3.1 Market Definition - Infoholic Research 12
3.2 Total Addressable Market 12
3.3 Segmented Addressable Market 13
3.4 Related Markets 14
3.4.1 Diabetes Drugs 14
3.4.2 Active Pharmaceutical Ingredients 15
3.4.3 Intragastric Balloon 15
3.4.4 Oncology (Cancer) Drugs 16
4 Market Outlook 16
4.1 Overview 16
4.2 Market Segmentation 17
4.3 Porter 5(Five) Forces 18
4.4 PEST Analysis 19
5 Market Characteristics 20
5.1 Market Evolution 20
5.2 Market Dynamics 21
5.2.1 Drivers 22
5.2.1.1 High prevalence of obesity 22
5.2.1.2 Unhealthy lifestyle 22
5.2.1.3 Chronic nature of obesity 23
5.2.2 Opportunities 23
5.2.2.1 Growing awareness of fitness 23
5.2.2.2 Large untapped market 23
5.2.3 Restraints 23
5.2.3.1 Side effects related to anti-obesity drugs 23
5.2.3.2 Availability of alternative treatment options 24
5.3 DRO - Impact Analysis 24
5.4 Key Stakeholders 25
6 Drug Details: Market Size and Analysis 26
6.1 Overview 26
6.2 Orlistat 27
6.3 Phentermine/Topiramate ER 27
6.4 Lorcaserin 28
6.5 Naltrexone SR/Bupropion SR 28
6.6 Liraglutide 3.0 mg 28
7 Types: Market Size and Analysis 29
7.1 Overview 29
7.2 Prescription Drugs (Rx) 29
7.3 OTC Drugs 30
8 Regions: Market Size and Analysis 31
8.1 Overview 31
8.2 North America 33
8.2.1 Overview 33
8.2.2 US 34
8.2.3 Canada 34
8.2.4 Mexico 34
8.3 Europe 35
8.3.1 Overview 35
8.3.2 UK 36
8.3.3 Germany 36
8.4 Asia Pacific 37
8.4.1 Overview 37
8.4.2 India 37
8.4.3 China 38
8.4.4 Australia 38
8.5 Rest of the World 38
8.5.1 Overview 38
8.5.2 Brazil 39
8.5.3 Africa 39
8.5.4 Middle East 39
9 Competitive Landscape 40
10 Vendors Profiles 42
10.1 F. Hoffmann-La Roche Ltd. 42
10.1.1 Overview 42
10.1.2 Business Units 45
10.1.3 Geographic Revenue 46
10.1.4 Business Focus 46
10.1.5 SWOT Analysis 47
10.1.6 Business Strategies 47
10.2 GlaxoSmithKline plc 48
10.2.1 Overview 48
10.2.2 Business Units 50
10.2.3 Geographic Revenue 51
10.2.4 Business Focus 52
10.2.5 SWOT Analysis 52
10.2.6 Business Strategies 53
10.3 Vivus' Inc. 53
10.3.1 Overview 53
10.3.2 Business Focus 55
10.3.3 SWOT Analysis 55
10.3.4 Business Strategies 56
10.4 Orexigen Therapeutics' Inc. 57
10.4.1 Overview 57
10.4.2 Business Focus 58
10.4.3 SWOT Analysis 59
10.4.4 Business Strategies 59
10.5 Eisai Co.' Ltd. 59
10.5.1 Overview 59
10.5.2 Geographic Revenue 61
10.5.3 Business Focus 61
10.5.4 SWOT Analysis 61
10.5.5 Business Strategies 62
11 Companies to Watch for 62
11.1 Pfizer' Inc. 63
11.1.1 Overview 63
11.1.2 Highlights 64
11.2 Nova Nordisk A/S 64
11.2.1 Overview 64
11.2.2 Highlights 65
11.3 Boehringer Ingelheim GmbH 65
11.3.1 Overview 65
11.4 Rhythm Pharmaceuticals' Inc. 66
11.4.1 Overview 66
11.5 Zafgen' Inc. 67
11.5.1 Overview 67
11.6 Norgine B.V. 67
11.6.1 Overview 67
11.7 Merck & Co. 68
11.7.1 Overview 68
11.7.2 Highlights 69
11.8 Takeda Pharmaceutical Co.' Ltd. 69
11.8.1 Overview 69
Annexure 70
Abbreviations 70
?